Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16135
|
| Title: | Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab |
| Authors: | Shen, YC;Liu, TH;Nicholas, A;Soyama, A;Yuan, CT;Chen, TC;Eguchi, S;Yoshizumi, T;Itoh, S;Nakamura, N;Kosaka, H;Kaibori, M;Ishii, T;Hatano, E;Ogawa, C;Naganuma, A;Kakizaki, S;Cheng, CH;Lin, PT;Su, YY;Chuang, CH;Lu, LC;Wu, CJ;Wang, HW;Rau, KM;Hsu, CH;Lin, SM;Huang, YH;Hernandez, S;Finn, RS;Kudo, M;Cheng, AL |
| Contributors: | National Institute of Cancer Research |
| Abstract: | PURPOSE: Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these patients and the histopathology of the residual tumors. PATIENTS AND METHODS: The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months was defined as durable. For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated. RESULTS: In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable. The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD. The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD. In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev. Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% v 16.7%, P = .034). PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150. We found no reliable radiologic features to predict PCR of the residual tumors. CONCLUSION: Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions. Early recognition of PCR lesions may help subsequent treatment decision. |
| Date: | 2024-12 |
| Relation: | Journal of Clinical Oncology. 2024 Dec;42(34):4060-4070. |
| Link to: | http://dx.doi.org/10.1200/jco.24.00645 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001363917400015 |
| Appears in Collections: | [蘇勇曄] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB39197119.pdf | | 1376Kb | Adobe PDF | 110 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
